A phase 1/2 trial of DS-3939a in advanced solid tumours, run by Daiichi Sankyo, now recruiting.
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05875168 by Daiichi Sankyo, with 590 participants planned, started 2023-08-18 and due to reach its primary completion in 2026-10-20. Interventions recorded: DS-3939a.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.